What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel

QJM: An International Journal of Medicine

Volumn 103, Issue 6, 2010, Pages 367-377

  Testa, L ^a,f   Bhindi, R ^b   Van Gaal, W J ^c,f   Latini, R A ^a,f   Pizzocri, S ^a   Lanotte, S ^a   Biondi Zoccai, G G L ^d,f   Valgimigli, M ^e   Laudisa, M L ^a   Brambilla, N ^a   Banning, A P ^d,f   Bedogni, F ^a,f  

^a S Ambrogio Clinical Institute   (Italy)

^b UNIVERSITY OF SYDNEY   (Australia)

^c NORTHERN HOSPITAL   (Australia)

^d UNIVERSITY OF TURIN   (Italy)

^e UNIVERSITY OF FERRARA   (Italy)

^f JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DRUG METABOLITE; KETOCONAZOLE; LANSOPRAZOLE; PLACEBO; PRASUGREL; R 138727; R 95913; THIENOPYRIDINE DERIVATIVE; THIOLACTIBE; TICLOPIDINE; UNCLASSIFIED DRUG; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; PIPERAZINE DERIVATIVE; PURINERGIC P2 RECEPTOR; PURINERGIC P2 RECEPTOR ANTAGONIST; THIOPHENE DERIVATIVE;

ACUTE CORONARY SYNDROME; BLEEDING; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG STRUCTURE; EX VIVO STUDY; HEART INFARCTION; HUMAN; HYDROLYSIS; LOW DRUG DOSE; META ANALYSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STENT THROMBOSIS; SYSTEMATIC REVIEW; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; DRUG ANTAGONISM; DRUG SCREENING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR;

DRUG EVALUATION, PRECLINICAL; HEMORRHAGE; HUMANS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2 RECEPTOR ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, PURINERGIC P2; RISK FACTORS; THIOPHENES; TICLOPIDINE;

EID: 79951993940     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcq017     Document Type: Review

References (59)

1. Kastrati A, Schomig A, Schomig E. Are we making efficient use of clopidogrel? Eur Heart J 2004; 25:454-6.
2. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502.
3. Gent M, Hampton JR, Roberts RS, Verstraete M, et al. A randomised, blinded trial of clopidogrel versus asprin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348:1329-39.
4. Fox K, Alonso Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, et al. Guidelines on the management of stable angina pectoris: executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27:1341-81.
5. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction) Developed in Collaboration With the Canadian Cardiovascular Society. (www.cardiosource.com) Accessed 21 May 2008.
6. ACC/AHA 2002 Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). [www.cardiosource.com] Accessed 21 May 2008..
7. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB 3rd et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006; 47:e1-121.
8. Angiolillo DJ, Alfonso F. Clopidogrel-statin interaction: myth or reality? J Am Coll Cardiol 2007; 50:296-8.
9. O'Donoghue M, Wiviott SD. Clopidogrel response variability and future therapies: clopidogrel: does one size fit all? Circulation 2006; 114:e600-6.
10. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109:3171-5.
11. Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007; 49:657-66.
12. Geisler T, Langer H, Wydymus M, Göhring K, Zürn C, Bigalke B, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006; 27:2420-5.
13. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009; 373:309-17.
14. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, et al. French registry of acute ST-elevation and non-ST-elevation myocardial infarction (FAST-MI) investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360:363-75.
15. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. 4. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360:354-62.
16. Jakubowski JA, Winters KJ, Naganuma H, Wallentin L. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 2007; 25:357-74.
17. Hagihara K, Kurihara A, Kawai K, Kazui M, Takahashi M, Kawabata K, et al. Absorption, distribution and excretion of the new thienopyridine agent prasugrel in rats. Xenobiotica 2007; 37:788-801.
18. Smith RL, Gillespie TA, Rash TJ, Kurihara A, Farid NA. Disposition and metabolic fate of prasugrel in mice, rats, and dogs. Xenobiotica 2007; 37:884-901.
19. Niitsu Y, Sugidachi A, Ogawa T, Jakubowski JA, Hashimoto M, Isobe T, et al. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species. Eur J Pharmacol 2008; 579:276-82.
20. Sugidachi A, Asai F, Yoneda K, Iwamura R, Ogawa T, Otsuguro K, et al. Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747. Br J Pharmacol 2001; 132:47-54.
21. Frelinger AL 3rd, Jakubowski JA, Li Y, Barnard MR, Fox ML, Linden MD, et al. The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: influence of other blood cells, calcium, and aspirin. Thromb Haemost 2007; 98:192-200.
22. Frelinger AL 3rd, Jakubowski JA, Li Y, Barnard MR, Linden MD, Tarnow I, et al. The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities. J Thromb Haemost 2008; 6:359-65.
23. Hasegawa M, Sugidachi A, Ogawa T, Isobe T, Jakubowski JA, Asai F. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor. Thromb Haemost 2005; 94:593-8.
24. Sugidachi A, Asai F, Ogawa T, Inoue T, Koike H. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol 2000; 129:1439-46.
25. Niitsu Y, Jakubowski JA, Sugidachi A, Asai F. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost 2005; 31:184-94.
26. Sugidachi A, Ogawa T, Kurihara A, Hagihara K, Jakubowski JA, Hashimoto M, et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogreĺs active metabolite. J Thromb Haemost 2007; 5:1545-51.
27. Asai F, Jakubowski JA, Naganuma H, Brandt JT, Matsushima N, Hirota T, et al. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans. Platelets 2006; 17:209-17.
28. Jakubowski JA, Payne CD, Brandt JT, Weerakkody GJ, Farid NA, Small DS, et al. The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects. J Cardiovasc Pharmacol 2006; 47:377-84.
29. Matsushima N, Jakubowski JA, Asai F, Naganuma H, Brandt JT, Hirota T, et al. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a multiple-dose study in healthy humans. Platelets 2006; 17:218-26.
30. Jakubowski JA, Payne CD, Weerakkody GJ, Brandt JT, Farid NA, Li YG, et al. Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects. J Cardiovasc Pharmacol 2007; 49:167-73.
31. Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007; 153:(66) e9-16.
32. Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS 2nd, Brandt JT, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007; 81:735-41.
33. Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS 2nd et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007; 5:2429-36.
34. Farid NA, Small DS, Payne CD, Jakubowski JA, Brandt JT, Li YG, et al. Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans. J Clin Pharmacol 2008; 48:53-9.
35. Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG, Brandt JT, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008; 48:475-84.
36. Weerakkody GJ, Jakubowski JA, Brandt JT, Farid NA, Payne CD, Zhu J, et al. Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status. Am J Cardiol 2007; 100:331-6.
37. Weerakkody GJ, Jakubowski JA, Brandt JT, Payne CD, Naganuma H, Winters KJ. Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis. J Cardiovasc Pharmacol Ther 2007; 12:205-12.
38. Payne CD, Li YG, Small DS, Ernest CS 2nd, Farid NA, Jakubowski JA, et al. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol 2007; 50:555-62.
39. Jakubowski JA, Matsushima N, Asai F, Naganuma H, Brandt JT, Hirota T, et al. A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol 2007; 63:421-30.
40. Wallentin L, Varenhorst C, James S, Erlinge D, Braun OO, Jakubowski JA, et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008; 29:21-30.
41. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation 2007; 116:2923-32.
42. Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the joint utilization of medications to block platelets optimally (JUMBO)-TIMI 26 trial. Circulation 2005; 111:3366-73.
43. Serebruany VL, Midei MG, Meilman H, Malinin AI, Lowry DR. Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study. Postgrad Med J 2006; 82:404-10.
44. Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006; 27:1166-73.
45. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357:2001-15.
46. Wiviott SD, Braunwald E, McCabe CH, Horvath I, Keltai M, Herrman JP, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITONTIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008; 371:1353-63.
47. von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A, Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (intracoronary stenting and antithrombotic regimen: choose between 3 high oral doses for immediate clopidogrel effect). Trial Circulation 2005; 112:2946-50.
48. Antman EM, Wiviott SD, Murphy SA, Voitk J, Hasin Y, Widimsky P, et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction) analysis. J Am Coll Cardiol 2008; 51:2028-33.
49. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrelthrombolysis in myocardial infarction 38. Circulation 2008; 118:1626-36.
50. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-segment elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomized controlled trial. Lancet 2009; 373:723-31.
51. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel. Relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009; 119:2553-60.
52. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007; 50:1822-34.
53. O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374:989-97.
54. The CRUSADE Bleeding Score to Assess Baseline Risk of Major Bleeding in Non-ST-Segment Elevation Myocardial Infarction. American College of Cardiology Annual Scientific Session, 2008.
55. Moscucci M, Fox KAA, Cannon CP, Klein W, López- Sendón J, Montalescot G, et al. Predictors of major bleeding in acute coronary syndromes: the global registry of acute coronary events (GRACE). Eur Heart J 2003; 20:1815-23.
56. Nikolsky E, Mehran R, Dangas G, Fahy M, Na Y, Pocock SJ, et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J 2007; 16:1936-45.
57. Mehta SK, Frutkin AD, Lindsey JB, House JA, Spertus JA, Rao SV, et al. Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry. Circ Cardiovasc Interv 2009; 2:222-9.
58. National Institute for Health and Clinical Excellence. Acute coronary syndrome-prasugrel: appraisal consultation document. [http://www.nice.org.uk/guidance/index.jsp?action=download&o=45321] Accessed 8 September 2009.
59. Collet JP, Silvain J, Landivier A, Tanguy ML, Cayla G, Bellemain A, et al. Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose. The reload with clopidogrel before coronary angioplasty in subjects treated long term with dual antiplatelet therapy (RELOAD) study. Circulation 2008; 118:1225-33.